<DOC>
	<DOCNO>NCT01290900</DOCNO>
	<brief_summary>This single dose study healthy male volunteer investigate effect high dos ceftazidime NXL104 ( CAZ104 ) ceftaroline fosamil NXL104 ( CXL104 ) QT interval</brief_summary>
	<brief_title>A Single-centre , Randomised , Double-blind , Placebo-controlled , Four Way Crossover Phase I Study Investigate Effect QT/QTc Interval Ceftazidime NXL104 Ceftaroline Fosamil NXL104 , Compared With Placebo , Using Moxifloxacin ( AveloxÂ® ) Positive Control , Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Avibactam</mesh_term>
	<mesh_term>Ceftazidime</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Provision sign informed consent prior study specific procedure Healthy male volunteer age 18 45 year ( inclusive ) suitable vein cannulation repeat venepuncture Have body mass index ( BMI ) 19 30 kg/m2 body weight 60 100 kg Be nonsmoker exsmoker stop smoke ( use nicotine product ) 3 month prior start study History clinically significant disease disorder , opinion Investigator , may either put volunteer risk participation study , influence result volunteer 's ability participate study Any clinically significant abnormality physical examination , clinical chemistry , haematology urinalysis result judge Investigator Abnormal vital sign , 10 minute supine rest , define follow : Systolic blood pressure ( SBP ) great 140 mmHg , Diastolic blood pressure ( DBP ) great 90 mmHg , Heart rate le 40 great 85 beat per minute Visit 1 Prolonged QTcF &gt; 450 m shorten QTcF &lt; 340 m Any clinically important abnormality rhythm , conduction morphology rest ECG may interfere interpretation QTc interval change . This include volunteer follow : Clinically significant PR ( PQ ) interval prolongation , Intermittent second third degree AV block ( Mobitz II type 1 , Wenchebach sleep disqualify ) , Incomplete , full intermittent bundle branch block ( QRS le 110 m normal QRS T wave morphology acceptable evidence leave ventricular hypertrophy ) , Abnormal T wave morphology , particularly protocol define primary lead</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>NXL104</keyword>
	<keyword>CAZ104</keyword>
	<keyword>Ceftazidime</keyword>
	<keyword>CXL104</keyword>
	<keyword>Ceftaroline</keyword>
	<keyword>Healthy Male Volunteers</keyword>
	<keyword>Phase 1</keyword>
	<keyword>OT</keyword>
	<keyword>Single Dose Study</keyword>
</DOC>